0000950170-25-102993
SEC filingRevenue declined 24% due to Natera phasing out, but clinical adoption accelerates with 59% sequential test volume growth.
In Q2 2025, total revenue declined 24% year-over-year to $17.2 million, driven primarily by a $5.6 million expected decline in enterprise sales from Natera and a $2.1 million decrease in pharma tests and services. Population sequencing partially offset the decline with a $2.0 million increase. Cost of revenue decreased 14% to $12.4 million, but the gross margin compressed to 27.6% from 35.6% in the prior year due to lower fixed overhead absorption and higher clinical diagnostic costs where reimbursement was below cost. Research and development expenses fell 4% to $12.4 million, reflecting reduced lab activities. Selling, general and administrative expenses rose 18% to $14.2 million due to expanded marketing programs for NeXT Personal Dx. The net loss widened to $20.1 million from $12.8 million, largely due to the absence of a $3.0 million noncash gain on Tempus warrants recognized in Q2 2024.
Revenue mix shifted significantly. Enterprise sales (primarily Natera) dropped 71% to $2.3 million as the partnership wound down, now comprising only 13% of total revenue versus 35% a year ago. Pharma tests and services fell 16% to $11.0 million due to fewer Moderna samples, although first-half revenue grew 7% on increased MRD demand. Population sequencing more than doubled to $3.3 million, benefiting from the fulfillment of a VA MVP task order. Clinical diagnostic revenue surged 301% to $0.5 million, driven by higher NeXT Dx volumes and early private payer reimbursements for NeXT Personal Dx. The 59% sequential increase in clinical test volumes (to 3,478) signals accelerating physician adoption.
Management expects enterprise sales from Natera to remain low as no long-term commercial relationship is anticipated. Population sequencing revenue will vary based on task order timing; the current order was fulfilled in Q2. Clinical diagnostics is a key growth driver, with expanding Tempus collaboration covering colorectal cancer and extended term through 2029. SG&A will continue to rise to support commercialization. Capital expenditures are planned at ~$7 million in 2025, increasing to $13-14 million annually in 2026-2027 to scale NeXT Personal Dx capacity. The company believes its $173 million cash and investments are sufficient for at least 12 months, but future capital needs may require additional financing.
As of June 30, 2025, Personalis held $53.4 million in cash and cash equivalents and $119.9 million in short-term investments, totaling $173.2 million in liquid assets. Total assets were $258.7 million, down from $270.3 million at December 31, 2024. Stockholders' equity decreased to $190.8 million from $203.0 million, primarily driven by a net loss of $35.8 million for the six months ended June 30, 2025, partially offset by $17.8 million in net proceeds from at-the-market equity offerings. The company had total debt of $2.7 million, including $2.6 million from a new software loan (January 2025 Agreement) and $1.8 million outstanding on a lab equipment loan, net of current portions. The company's accumulated deficit reached $585.8 million, reflecting ongoing operating losses.
The most significant contractual obligation is the company's operating leases, with total future minimum lease payments of $66.3 million as of June 30, 2025. The present value of these lease payments, discounted at a weighted-average rate of 10.6%, was $40.6 million. Lease payments due within the next twelve months amount to $7.8 million, with $14.4 million due in 1-3 years and $48.0 million beyond three years. Additionally, the company has a loan payable of $2.7 million, including $0.9 million due within one year and $0.8 million in long-term portion. There were no other material purchase commitments or contractual obligations disclosed beyond these.
The company did not repurchase any shares or pay dividends during the period. Capital expenditures were $2.8 million for the six months ended June 30, 2025, primarily for purchases of property and equipment. The company raised $17.8 million in net proceeds from at-the-market equity offerings during the six months. Debt issuance was $2.6 million from a new software loan, while repayments totaled $1.3 million. The company's capital allocation strategy remains focused on funding operations and investment in growth, as evidenced by continued cash burn from operations ($30.9 million used in operating activities for the six months).
The company operates as a single reportable segment: advanced cancer genomic tests and services. However, it provides disaggregated revenue by customer type. For the six months ended June 30, 2025, pharma tests and services contributed $24.6 million (65% of total), population sequencing $7.5 million (20%), enterprise sales $4.8 million (13%), clinical diagnostic $0.8 million (2%), and other $0.1 million. Geographically, 91% of revenue came from the United States and 9% from other regions. Customer concentration is high: ModernaTX accounted for 28% of revenue, VA MVP 20%, and Natera 13% during the first half of 2025.
Personalis reported a net loss of $35.8M in H1 2025, widening from $25.8M in H1 2024. Despite this, cash used in operations improved slightly to $30.9M from $31.2M, driven by non-cash charges (stock-based compensation, depreciation) and favorable working capital swings (accounts payable increased $3.7M vs a decrease of $5.1M). However, accounts receivable increased by $1.8M, and contract liabilities fell.
Capital expenditures surged to $2.8M (from $0.1M), indicating increased investment in property and equipment. Free cash flow (not explicitly stated) would be approximately $(33.7)M (operating cash flow minus capex), worsening from $(31.3)M. The company financed operations through ATM sales ($17.8M) and loans ($2.6M), while repaying $1.3M in loans. No share repurchases or dividends were made.
Overall, cash burn remains high, with capex intensity increasing. The company relied on external financing to cover the cash deficit, resulting in a net decrease in cash of $38.0M for the period.